Jillian Wilhelmina Paulina Bracht1, Clara Mayo-de-Las-Casas1, Jordi Berenguer1, Niki Karachaliou2,3, Rafael Rosell4,5,6,7. 1. Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Sabino Arana 5-19, 08028, Barcelona, Spain. 2. Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Sabino Arana 5-19, 08028, Barcelona, Spain. nkarachaliou@oncorosell.com. 3. Instituto Oncológico Dr Rosell (IOR), University Hospital Sagrat Cor, QuironSalud Group, Viladomat 288, 08029, Barcelona, Spain. nkarachaliou@oncorosell.com. 4. Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Sabino Arana 5-19, 08028, Barcelona, Spain. rrosell@iconcologia.net. 5. Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, 08916, Badalona, Barcelona, Spain. rrosell@iconcologia.net. 6. Institut d'Investigació en Ciències Germans Trias i Pujol, Camí de les Escoles, s/n, 08916, Badalona, Barcelona, Spain. rrosell@iconcologia.net. 7. Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Sabino Arana 5-19, 08028, Barcelona, Spain. rrosell@iconcologia.net.
Abstract
PURPOSE OF REVIEW: Liquid biopsies have potential as tools for diagnosis, prognosis, and prediction of response to therapy. Herein, we will extensively review four liquid biosources, tumor-educated platelets (TEPs), cell-free DNA (cfDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) and we will clarify their optimal application in non-small cell lung cancer (NSCLC) diagnosis and therapy. RECENT FINDINGS: Liquid biopsies are a minimally invasive alternative to tissue biopsies-especially important in NSCLC patients-since tumor tissue is often unavailable or insufficient for complete genetic analysis. The main advantages of liquid biopsies include the possibility for repeated sampling, the lower cost, and the fact that they can reflect the complete molecular status of the patient better than a single-site biopsy. This is specifically important for lung adenocarcinoma patients since the detection of specific genetic alterations can predict response to targeted therapies. Molecular analysis is currently cardinal for therapy decision-making and disease monitoring in lung cancer patients. Liquid biopsies can make easier our daily clinical practice and if prospectively tested and validated may serve as a means for lung cancer early detection.
PURPOSE OF REVIEW: Liquid biopsies have potential as tools for diagnosis, prognosis, and prediction of response to therapy. Herein, we will extensively review four liquid biosources, tumor-educated platelets (TEPs), cell-free DNA (cfDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) and we will clarify their optimal application in non-small cell lung cancer (NSCLC) diagnosis and therapy. RECENT FINDINGS: Liquid biopsies are a minimally invasive alternative to tissue biopsies-especially important in NSCLCpatients-since tumor tissue is often unavailable or insufficient for complete genetic analysis. The main advantages of liquid biopsies include the possibility for repeated sampling, the lower cost, and the fact that they can reflect the complete molecular status of the patient better than a single-site biopsy. This is specifically important for lung adenocarcinomapatients since the detection of specific genetic alterations can predict response to targeted therapies. Molecular analysis is currently cardinal for therapy decision-making and disease monitoring in lung cancerpatients. Liquid biopsies can make easier our daily clinical practice and if prospectively tested and validated may serve as a means for lung cancer early detection.
Authors: Kathrin Dvir; Gliceida M Galarza-Fortuna; Joel M Haines; Paulina Gines; Ana L Ruiz; Estelamari Rodriguez Journal: J Immunother Precis Oncol Date: 2021-02-03
Authors: Teofila Seremet; Yanina Jansen; Simon Planken; Hassan Njimi; Mélanie Delaunoy; Hakim El Housni; Gil Awada; Julia Katharina Schwarze; Marleen Keyaerts; Hendrik Everaert; Danielle Lienard; Véronique Del Marmol; Pierre Heimann; Bart Neyns Journal: J Transl Med Date: 2019-09-05 Impact factor: 5.531
Authors: Daan van den Broek; T Jeroen N Hiltermann; Bonne Biesma; Winand N M Dinjens; Nils A 't Hart; John W J Hinrichs; Mathie P G Leers; Kim Monkhorst; Matthijs van Oosterhout; Volkher Scharnhorst; Ed Schuuring; Ernst-Jan M Speel; Michel M van den Heuvel; Ron H N van Schaik; Jan von der Thüsen; Stefan M Willems; Leonie de Visser; Marjolijn J L Ligtenberg Journal: Front Oncol Date: 2020-01-22 Impact factor: 6.244